Thromboembolic disease in vasculitis

Current Opinion in Rheumatology

Volumn 21, Issue 1, 2009, Pages 41-46

  Tomasson, Gunnar ^a   Monach, Paul A ^a   Merkel, Peter A ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ANCA; Antineutrophil cytoplasmic antibodies; Behcet's disease; Microscopic polyangiitis; Thrombosis; Vasculitis; Wegener's granulomatosis

Indexed keywords

ANTICOAGULANT AGENT; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY;

BEHCET DISEASE; BLOOD CLOTTING; CLINICAL FEATURE; COHORT ANALYSIS; COMPREHENSION; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEEDBACK SYSTEM; HUMAN; INFLAMMATION; INTROSPECTION; LABORATORY TEST; LUNG EMBOLISM; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM; VASCULITIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

AUTOANTIBODIES; BEHCET SYNDROME; BIOLOGICAL MARKERS; BLOOD COAGULATION DISORDERS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOTHERAPY; NEUTROPHILS; THROMBOEMBOLISM; VASCULITIS;

EID: 58149216465     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32831de4e7     Document Type: Review

References (62)

1. von Scheven E, Lu TT, Emery HM, et al. Thrombosis and pediatric Wegener's granulomatosis: acquired and genetic risk factors for hypercoagulability. Arthritis Rheum 2003; 49:862-865.
2. Merkel PA, Lo GH, Holbrook JT, et al. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. Ann Intern Med 2005; 142:620-626.
3. Weidner S, Hafezi-Rachti S, Rupprecht HD. Thromboembolic events as a complication of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2006; 55:146-149.
4. Stassen PM, Derks RP, Kallenberg CG, Stegeman CA. Venous thromboem- • bolism in ANCA-associated vasculitis: incidence and risk factors. Rheumatology (Oxford) 2008; 47:530-534. Third report showing an increased risk of venous thrombosis in ANCA-associated vasculitis.
5. Allenbach Y, Pagnoux C, Seror R, et al. Venous thromboembolic events in patients with different systemic necrotizing vasculitides: systematic study of on the French vasculitis study group (FVSG) patient cohort. Arthr Rheum 2007; 56:S767.
6. Hansson PO, Welin L, Tibblin G, Eriksson H. Deep vein thrombosis and pulmonary embolism in the general population: 'The Study of Men Born in 1913'. Arch Intern Med 1997; 157:1665-1670.
7. The WGET Research Group. The Wegener's Granulomatosis Etanercept Trial (WGET): randomized, double-masked, placebo-controlled trial of etanercept for the induction and maintenance of remission. New Eng J Med 2005;352:351-361.
8. Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001; 44:912-920.
9. The WGET Research Group. Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin Trials 2002; 23:450-468.
10. Sebastian JK, Voetsch B, Stone JH, et al. The frequency of anticardiolipin • antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J Rheumatol 2007; 34:2446-2450. Cohort study finding an absence of several known risk factors for a hypercoagulable state among patients with Wegener's granulomatosis and thrombosis.
11. al-Dalaan AN, al Balaa SR, el Ramahi K, et al. Behcet's disease in Saudi Arabia. J Rheumatol 1994; 21:658-661.
12. Ames PR, Steuer A, Pap A, Denman AM. Thrombosis in Behcet's disease: a retrospective survey from a single UK centre. Rheumatology (Oxford) 2001; 40:652-655.
13. Düzgün N, Ates A, Aydintug OT, et al. Characteristics of vascular involvement in Behcet's disease. Scand J Rheumatol 2006; 35:65-68.
14. Gurler A, Boyvat A, Tursen U. Clinical manifestations of Behçet's disease: an analysis of 2147 patients. Yonsei Med J 1997; 38:423-427.
15. Koc Y, Gullu I, Akpek G, et al. Vascular involvement in Behcet's disease. J Rheumatol 1992; 19:402-410.
16. Mousa AR, Marafie AA, Rifai KM, et al. Behcet's disease in Kuwait, Arabia. A report of 29 cases and a review. Scand J Rheumatol 1986; 15:310-332.
17. Sarica-Kucukoglu R, Akdag-Kose A, Kayabal IM, et al. Vascular involvement in Behcet's disease: a retrospective analysis of 2319 cases. Int J Dermatol 2006; 45:919-921.
18. Shahram F, Nadji A, Ahmad-Reza J, et al. Behçet's disease in Iran, analysis of 5059 cases. Arch Iranian Med 2004; 7:9-14.
19. Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd-Chiari syndrome: a common complication of Behcet's disease. Am J Gastroenterol 1997; 92:858-862.
20. Mogulkoc N, Burgess Ml, Bishop PW. Intracardiac thrombus in Behcet's disease: a systematic review. Chest 2000; 118:479-487.
21. Tunc R, Saip S, Siva A, Yazici H. Cerebral venous thrombosis is associated with major vessel disease in Behcet's syndrome. Ann Rheum Dis 2004; 63:1693-1694.
22. Lakhanpal S, Tani K, Lie JT, et al. Pathologic features of Behcet's syndrome: a review of Japanese autopsy registry data. Hum Pathol 1985; 16:790-795.
23. Uzun O, Akpolat T, Erkan L. Pulmonary vasculitis in behcet disease: a cumulative analysis. Chest 2005; 127:2243-2253.
24. Tunaci M, Ozkorkmaz B, Tunaci A, et al. CT findings of pulmonary artery aneurysms during treatment for Behcet's disease. AJR Am J Roentgenol 1999; 172:729-733.
25. Ahn JK, Lee YS, Jeon CH, et al. Treatment of venous thrombosis associated • with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008; 27:201 - 205. A small retrospective study that raises intriguing questions about the role of immunosuppression versus anticoagulation for the treatment of thrombosis in Behcet's disease.
26. Espinosa G, Font J, Tassies D, et al. Vascular involvement in Behcet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin [see comment]. Am J Med 2002; 112:37-43.
27. Hull RG, Harris EN, Gharavi AE, et al. Anticardiolipin antibodies: occurrence in Behcet's syndrome. Ann Rheum Dis 1984; 43:746-748.
28. Leiba M, Seligsohn U, Sidi Y, et al. Thrombophilic factors are not the leading cause of thrombosis in Behcet's disease. Ann Rheum Dis 2004; 63:1445- 1449.
29. Mader R, Ziv M, Adawi M, Lavi I. Thrombophilic factors and their relation to thromboembolic and other clinical manifestations in Behcet's disease. J Rheumatol 1999; 26:2404-2408.
30. Silingardi M, Salvarani C, Boiardi L, et al. Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behcet's disease and deep vein thrombosis. Arthritis Rheum 2004; 51:177-183.
31. Efthimiou J, Harris EN, Hughes GR. Negative anticardiolipin antibodies and vascular complications in Behcet's syndrome. Ann Rheum Dis 1985; 44:725-726.
32. Zouboulis CC, Buttner P, Tebbe B, Orfanos CE. Anticardiolipin antibodies in Adamantiades-Behcet's disease. Br J Dermatol 1993; 128:281 -284.
33. Ricart JM, Vaya A, Todoli J, et al. Thrombophilic risk factors and homocysteine levels in Behcet's disease in eastern Spain and their association with thrombotic events. Thromb Haemost 2006; 95:618-624.
34. Seriolo B, Cutolo M, Garnero A, Accardo S. Risk factors for thrombotic events in giant cell arteritis and polymyalgia rheumatica. Br J Rheumatol 1998; 37:1251-1253.
35. Manna R, Latteri M, Cristiano G, et al. Anticardiolipin antibodies in giant cell arteritis and polymyalgia rheumatica: a study of 40 cases. Br J Rheumatol 1998;37:208-210.
36. Nuenninghoff DM, Hunder GG, Christianson TJ, et al. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003; 48:3522-3531.
37. Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50:1332-1337.
38. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 2006; 54:3306- 3309.
39. Sharma S, Taneja K, Gupta AK, Rajani M. Morphologic mural changes in the aorta revealed by CT in patients with nonspecific aortoarteritis (Takayasu's arteritis). AJR Am J Roentgenol 1996; 167:1321-1325.
40. Purkayastha S, Jayadevan ER, Kapilamoorthy TR, et al. Suction thrombectomy of thrombotic occlusion of the subclavian artery in a case of Takayasu's arteritis. Cardiovasc Intervent Radiol 2006; 29:289-293.
41. Hulusi M, Basaran M, Yilmaz AT. Carotid and coronary artery occlusion in a patient with Takayasu arteritis. J Card Surg 2007; 22:352-355.
42. Dasgupta B, Almond MK, Tanqueray A. Polyarteritis nodosa and the antiphospholipid syndrome. Br J Rheumatol 1997; 36:1210-1212.
43. Han BK, Inaganti K, Fahmi S, Reimold A. Polyarteritis nodosa complicated by catastrophic antiphospholipid syndrome. J Clin Rheumatol 2004; 10:210- 213.
44. Musuruana JL, Cavallasca JA. Polyarteritis nodosa complicated by antiphospholipid syndrome. South Med J 2008; 101:419-421.
45. Yamasaki S, Tominaga M, Kawakami A, et al. Polyarteritis nodosa complicated by thrombotic thrombocytopenic purpura. Ann Rheum Dis 2001; 60:541 - 542.
46. Kato H, Ichinose E, Yoshioka F, et al. Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and long-term follow-up study. Am J Cardiol 1982; 49:1758-1766.
47. Wang CL, Wu YT, Liu CA, et al. Expression of CD40 ligand on CD4+ T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Pediatrics 2003; 111:E140-E147.
48. Maeno N, Takei S, Masuda K, et al. Increased serum levels of vascular endothelial growth factor in Kawasaki disease. Pediatr Res 1998; 44:596-599.
49. Abend NS, Licht DJ, Spencer CH, et al. Lupus anticoagulant and thrombosis following Henoch-Schonlein purpura. Pediatric Neurology 2007; 36:345- 347.
50. Sari I, Akar S, Secil M, et al. Thrombosis and priapism in a patient with Henoch-Schonlein purpura. Rheumatol Int 2005; 25:472-474.
51. Monastiri K, Selmi H, Tabarki B, et al. Primary antiphospholipid syndrome presenting as complicated Henoch-Schonlein purpura. Arch Dis Child 2002; 86:132-133.
52. Roumen-Klappe EM, den Heijer M, van Uum SH, et al. Inflammatory response in the acute phase of deep vein thrombosis. J Vasc Surg 2002; 35:701 - 706.
53. van Aken BE, den Heijer M, Bos GM, et al. Recurrent venous thrombosis and markers of inflammation. Thromb Haemost 2000; 83:536-539.
54. Koutroubakis IE, Theodoropoulou A, Xidakis C, et al. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004; 16:1147-1152.
55. McEntegart A, Capell H, Creran D, et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology 2001; 40:640-644.
56. Bajema IM, Bruijn JA. What stuff is this! A historical perspective on fibrinoid necrosis. J Pathol 2000; 191:235-238.
57. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; • 359:938-949. A comprehensive review with a detailed discussion of the role of inflammation in the pathogenesis of thrombosis.
58. Rauch U, Nemerson Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med 2000; 10:139-143.
59. Woywodt A, Streiber F, de Groot K, et al. Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet 2003; 361:206-210.
60. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391:591 - 594.
61. Slupsky JR, Kalbas M, Willuweit A, et al. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thromb Haemost 1998; 80:1008-1014.
62. Li CG, Reynolds I, Ponting JM, et al. Serum levels of vascular endothelial growth factor (VEGF) are markedly elevated in patients with Wegener's granulomatosis. Br J Rheumatol 1998; 37:1303-1306.